Knight Therapeutics Inc. (FRA:04K)

Market Cap	370.81M
Revenue (ttm)	253.23M
Net Income (ttm)	-2.14M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	193.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	3.720
Previous Close	3.720
Day's Range	3.720 - 3.720
52-Week Range	3.400 - 4.040
Beta	n/a
RSI	53.31
Earnings Date	Mar 19, 2026

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Pharmaceutical Preparations
• Founded: 2013
• Employees: 745
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 04K

Financial Performance

Financial numbers in CAD